Morgan Stanley analyst Judah Frommer downgraded Galapagos (GLPG) to Underweight from Equal Weight with a price target of $22, down from $31. The Deprioritization of GLPG5201 in CLL/RT – Chronic lymphocytic leukemia, Richter’s Transformation – leads the firm to lower its probability of success in these indications within its model, the analyst tells investors in a research note. Morgan Stanley adds that value inflection potential catalysts for Galapagos are likely over 12 months away as the firm awaits incremental clinical activity within the ‘5101 program.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GLPG:
- Galapagos downgraded to Underweight from Equal Weight at Morgan Stanley
- Galapagos NV Announces Strategic Separation Agreement with Gilead
- GLPG Earnings this Week: How Will it Perform?
- Galapagos downgraded to Underweight from Equal Weight at Barclays
- Galapagos to reduce workforce by 40%, end small molecule discovery programs